New trials, publications, preprints and grants on this target, month by month.
Trial
Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer
1 Jun 2027· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer
1 Jan 2027· PHASE1_PHASE2 · RECRUITING· CTGOV
Trial
CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM)
1 Jan 2027· PHASE1 · NOT_YET_RECRUITING· CTGOV
Trial
Real-World Study: Panitumumab N01 vs Cetuximab Plus FOLFOX in First-Line RAS Wild-Type mCRC
1 Jan 2027· NA · NOT_YET_RECRUITING· CTGOV
Trial
Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)
1 Dec 2026· PHASE3 · NOT_YET_RECRUITING· CTGOV
Trial
A Clinical Study Comparing the Efficacy and Safety of Befotertinib Versus Icotinib in Patients With Previously Untreated EGFR-sensitive Mutation-positive Non-small Cell Lung Cancer With ECOG Score ≥2
30 Nov 2026· PHASE4 · NOT_YET_RECRUITING· CTGOV
Trial
Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients
30 Nov 2026· PHASE2 · RECRUITING· CTGOV
Trial
Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
30 Nov 2026· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Effects of a Visual Interactive LINE Chatbot on Self-Management of EGFR-TKI Related Side Effects in Patients With Lung Cancer
10 Nov 2026· NA · NOT_YET_RECRUITING· CTGOV
Publication
TAVO412, an Anti-EGFR, cMET and VEGF Trispecific Antibody: Initial Results from a Phase I Dose Escalation Study in Patients with Advanced Solid Tumors.
6 Nov 2026· The oncologist· PUBMED
Publication
Impact of Dosage Modifications on Efficacy: Insights from Select Tyrosine Kinase Inhibitors Approved for Treatment of Non-Small Cell Lung Cancer with EGFR Mutations.
6 Nov 2026· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Publication
RHBDL2 promotes cancer stemness and chemoresistance in triple-negative breast cancer through EGFR/PI3K/AKT/mTOR/c-Myc pathway.
5 Nov 2026· Oncogene· PUBMED
Publication
BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor against Uncommon EGFR Mutations.
3 Nov 2026· Molecular cancer therapeutics· PUBMED
Publication
Panitumumab-Based EGFR Blockade in SMARCB1-Deficient Renal Medullary Carcinoma: Preclinical Basis and Prospective Clinical Activity.
2 Nov 2026· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Publication
EMB-01, an Anti-EGFR/c-MET Bispecific Antibody, in Patients with Heavily Pretreated Metastatic Colorectal Cancer from a Phase Ib/II, Open-Label, Multicenter Study.
2 Nov 2026· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Publication
β-elemene suppressed EMT via IGF1R inhibition in osimertinib treated AXL low-expressing EGFR mutant non-small cell lung cancer.
2 Nov 2026· European journal of pharmacology· PUBMED
Publication
PIP3 and EGFR Dual Targeting for the Development of a Polypeptide Complex Drug Aimed at the Specific Delivery and Therapy of Anaplastic Thyroid Carcinoma.
2 Nov 2026· Molecular pharmaceutics· PUBMED
Trial
FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)
1 Nov 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Adjuvant ctDNA-Adapted Treatment With Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLC
1 Nov 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
MRD-Guided Aumolertinib-Based Adjuvant Therapy for Resected EGFR-Mutant NSCLC
1 Nov 2026· NA · NOT_YET_RECRUITING· CTGOV
Trial
Firmonertinib Plus Chemotherapy for Unresectable EGFR PACC-Mutant Stage III Lung Cancer: A Phase II Study
1 Nov 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
Predicting early EGFR-TKI treatment response in EGFR-mutant lung adenocarcinoma from H&E histopathology with weakly supervised multiple-instance learning.
1 Nov 2026· Pathology, research and practice· PUBMED
Publication
Protocol of a Real-World Prospective Observational Study of Amivantamab Plus Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (SPIRAL-RACER20 Study).
1 Nov 2026· Thoracic cancer· PUBMED
Publication
Profiling EGFR, c-MET, and B7H3 co-expression to guide next-generation dual-drug conjugate strategies in colorectal cancer.
1 Nov 2026· The journal of pathology. Clinical research· PUBMED
Publication
Transformation to Small-Cell Lung Carcinoma and Then to Sarcomatoid Carcinoma in an EGFR-Mutant Lung Adenocarcinoma Patient During Systemic Therapy: A Case Report.
1 Nov 2026· Thoracic cancer· PUBMED
Publication
Targeting the TBK1-p62 condensate axis restores sensitivity to EGFR-TKIs in resistant lung cancer.
1 Nov 2026· Protein & cell· PUBMED
Publication
Machine learning-assisted Ti3C2Tx MXene/Au@Fe3O4 core-shell nanocomposite-based electrochemical genosensor for ultrasensitive detection of EGFR T790M mutation in lung cancer.
31 Oct 2026· Mikrochimica acta· PUBMED
Trial
ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
30 Oct 2026· PHASE3 · NOT_YET_RECRUITING· CTGOV
Trial
Real-World Treatment Patterns and Effectiveness of Anti-EGFR- and Anti-VEGF-based Therapies in Left-sided RAS Wild-Type Metastatic Colorectal Cancer
30 Oct 2026· NA · NOT_YET_RECRUITING· CTGOV
Publication
Brief report: Clinical and Functional Characterization of Rare Germline and Somatic EGFR Variants in Three Patients with Non-Small Cell Lung Cancer.
30 Oct 2026· Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer· PUBMED